Tests C-peptide during low blood sugar in adults with type 1 diabetes
Tests C-peptide in adults with type 1 diabetes during insulin-induced low blood sugar.
Key facts
- Who runs it
- University of Cincinnati
- Where
- Cincinnati, United StatesSee the site
- Trial code
- Registry title
- Effect of C-peptide on Hypoglycemic Counterregulation
- Status
- Recruiting
- Phase
- Early phase 1
- People taking part
- 38 people, planned
- Started
- 1 Jun 2024
- Expected to end
- 1 Jan 2028
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Saline
- C-peptide
- Record updated
- 17 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 40 with a BMI under 30 kg/m2. It studies how C-peptide affects the body's response to low blood sugar.
- Age
- 18 to 40 years
- Sex
- All sexes can join.
Main reasons for not taking part
- Pregnant or breastfeeding women
- Cigarette smoking
- HIV or hepatitis
- Cardiovascular disease
- Microvascular disease
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- BMI less than 30 kg/m2
Who cannot take part
- pregnant or lactating women cigarette smoking presence of HIV or hepatitis presence of cardiovascular disease presence of microvascular disease
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 40 years old?
Where in United States
- University of CincinnatiCincinnati, United StatesContact: Jason Winnick, PhDTaking people
About the trial
What the trial wants to find out
Iatrogenic hypoglycemia is the most prominent barrier to the safe, effective management of blood sugar in people with type 1 diabetes due to periodic over-insulinization. During insulin-induced hypoglycemia, glucagon secretion is diminished in type 1 diabetes which, in turn, reduces hepatic glucose production and increases the depth and duration of hypoglycemic episodes. We have observed that the naturally occurring protein C-peptide increases glucagon secretion in dogs during insulin-induced hypoglycemia, which increases hepatic glucose production; the experiments in this application will shed light on the translation of this finding to the human.
The 4 groups in the trial
- Healthy Control- SalinePlacebo, for comparison
Saline will be infused in healthy control subjects during insulin-induced hypoglycemia
Treatment: Saline
- Healthy Control- C-peptideExisting treatment, for comparison
C-peptide will be infused in healthy control subjects during insulin-induced hypoglycemia
Treatment: C-peptide
- T1D- SalinePlacebo, for comparison
Saline will be infused in T1D subjects during insulin-induced hypoglycemia
Treatment: Saline
- T1D- C-peptideExisting treatment, for comparison
C-peptide will be infused in T1D subjects during insulin-induced hypoglycemia
Treatment: C-peptide
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- On the Regulation of Hepatic Glucose Metabolism During Insulin-induced Hypoglycemia
- Plain-language title
- Tests C-peptide during low blood sugar in adults with type 1 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06470295, who can take part
- Record updated
- 17 February 2026